Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Elan Corp.
Current Parent Company: Perrigo
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $43,399,040
Year: 2010
Date: December 16, 2010
Offense Group: healthcare-related offenses
Primary Offense: off-label or unapproved promotion of medical products
Secondary Offense: False Claims Act and related
Mega-Scandal: Improper Drug Marketing
Violation Description: Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $43 million to settle multistate litigation alleging that they illegally promoted the epilepsy drug Zonegran for uses not approved by the Food and Drug Administration and that this caused false claims to be submitted to state Medicaid programs. This was part of a larger $203 million civil and criminal settlement involving the federal government; see the Violation Tracker entry at (click here)
Level of Government: state
Action Type: agency action
Agency: Multistate Attorneys General Case
Civil or Criminal Case: civil
HQ Country of Current Parent: Ireland
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.